Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4 /6 inhibitor in HR ‐positive/ HER2 ‐negative metastatic breast cancer: A prospective study
Thoracic Cancer · 2024-04 · 15 (12) · 965-973
DOI: 10.1111/1759-7714.15282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 13.03.2024. Verfasst von Yun Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Background
CDK4/6 inhibitors in combination with traditional endocrine therapy (ET) have become the recommended first‐line therapy for HR‐positive/HER2‐negative metastatic breast cancer (MBC). The aim of this prospective study was to evaluate the relationship between HER2‐low expression and clinical outcomes in HR‐positive/HER2‐negative MBC patients receiving ET with or without CDK4/6 inhibitors.
Methods
Between April 2016 and November 2019, 233 women with HR‐positive/HER2‐negative MBC who received ET with or without CDK4/6 inhibitors were enrolled into the study. The primary endpoint was progression‐free survival (PFS). Statistical analysis included descriptive statistics, Kaplan–Meier curves, and Cox proportional hazards models.
Results
HER2‐low and HER2‐zero subgroups in the CDK4/6 inhibitor plus ET cohort showed no significant difference in the median PFS (10.9 vs. 8.0 months; hazard ratio: 0.92; 95% confidence interval [CI]: 0.64–1. 30; p = 0.65), while HER2‐low subgroup showed a significantly shorter median PFS compared to the HER2‐zero subgroup in the ET alone cohort (5.6 vs. 17.0 months; hazard ratio: 2.82; 95% CI: 1.34–5.93; p = 0.0044). Moreover, the objective response rate was significantly lower in the HER2‐low subgroup than the HER2‐zero subgroup in the ET alone cohort (10.5% vs. 40.0%, p = 0.047). Lastly, no significant difference was observed in the overall survival between the HER2‐low and HER2‐zero subgroups in both cohorts.
Conclusion
This study suggested that HER2‐low expression may predict the efficacy of ET but not that of CDK4/6 inhibitor plus ET in HR‐positive/HER2‐negative MBC patients. The results of this study highlight the importance of integrating HER2 status in tailoring personalized treatment strategies for HR‐positive MBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Förderung
- National Key Research and Development Program of China
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Wu, Y., Mo, H., Xu, H., Wang, Y., Wang, J., Ma, F., & Xu, B. (2024). Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4 /6 inhibitor in HR ‐positive/ HER2 ‐negative metastatic breast cancer: A prospective study. Thoracic Cancer, 15(12), 965-973. https://doi.org/10.1111/1759-7714.15282
Vancouver
Wu Y, Mo H, Xu H, Wang Y, Wang J, Ma F, et al. Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4 /6 inhibitor in HR ‐positive/ HER2 ‐negative metastatic breast cancer: A prospective study. Thoracic Cancer. 2024;15(12):965-973. doi:10.1111/1759-7714.15282
BibTeX
@article{Wu2024,
author = {Wu, Yun and Mo, Hongnan and Xu, Hangcheng and Wang, Yan and Wang, Jiayu and Ma, Fei and Xu, Binghe},
title = {Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4 /6 inhibitor in HR ‐positive/ HER2 ‐negative metastatic breast cancer: A prospective study},
journal = {Thoracic Cancer},
year = {2024},
volume = {15},
number = {12},
pages = {965--973},
doi = {10.1111/1759-7714.15282}
}
EUVIMED